Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NanoString Technologies Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
NanoString Technologies Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
NanoString Technologies Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
NanoString Technologies Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
NanoString Technologies Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
NanoString Technologies Inc, Medical Equipment, Deal Details 12
Venture Financing 12
NanoString Technologies Raises US$0.2 Million In Venture Financing 12
NanoString Technologies Raises US$15 Million In Series E Financing 13
NanoString Technologies To Raise US$0.65 Million In Venture Financing 15
NanoString Technologies Secures US$20 Million In Series D Financing 16
NanoString Technologies Secures US$2.5 Million In Venture Financing 17
Partnerships 18
NanoString Technologies Enters into Distribution Agreement with SAM Laboratory 18
NanoString Technologies Enters into Agreement with NSABP Foundation 19
NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 20
NanoString Technologies Enters into Co-Development Agreement with HalioDx 21
NanoString Technologies Enters into Agreement with Cell Signaling Technology 22
Medivation and NanoString Technologies Enters into Partnership With Astellas Pharma 23
NanoString Enters into Research Agreement with CITN for Novel Cancer Immunotherapies 24
NanoString Enters into Co-Development Agreement with MD Anderson Cancer Center 25
NanoString Enters into Research Agreement with Brigham and Women’s Hospital 26
NanoString Enters into Co-Development Agreement with Celgene 27
NanoString Technologies Enters Into Option Agreement With Broad Institute To License Liver Cancer Gene Signature 28
Equity Offering 29
NanoString Technologies Plans to Raise USD100 Million in Public Offering of Shares 29
NanoString Technologies Raises USD57.8 Million in Public Offering of Shares 30
NanoString to Raise USD40 Million in Public Offering of Shares 32
NanoString Technologies Completes Public Offering Of Shares For US$55 Million 33
NanoString Technologies Completes IPO Of Shares For US$54 Million 35
NanoString Technologies Inc – Key Competitors 37
NanoString Technologies Inc – Key Employees 38
NanoString Technologies Inc – Locations And Subsidiaries 39
Head Office 39
Recent Developments 40
Financial Announcements 40
May 04, 2017: NanoString Technologies Releases Operating Results for First Quarter of 2017 40
Mar 01, 2017: NanoString Technologies Releases Fourth Quarter and Full Year 2016 Operating Results and Provides 2017 Outlook 41
Jan 10, 2017: NanoString Technologies Provides Preliminary Operational and Financial Results for 2016 42
Nov 02, 2016: NanoString Technologies Releases Operating Results for Third Quarter of 2016 43
Aug 03, 2016: NanoString Technologies Releases Operating Results for Second Quarter of 2016 44
May 05, 2016: NanoString Technologies Releases Operating Results for First Quarter of 2016 45
Feb 29, 2016: NanoString Technologies Releases Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Outlook 46
Jan 10, 2016: NanoString Technologies Provides Preliminary Operational and Financial Results for 2015 48
Corporate Communications 49
May 10, 2017: NanoString Appoints Elisha W. Finney to Board of Directors 49
Sep 13, 2016: NanoString Technologies Appoints Kirk Malloy, Ph.D. to Board of Directors 50
Product News 51
Sep 18, 2017: NanoStrings Hyb & Seq Enables Liquid Biopsy by the Direct Capture and Sequencing of Cell-Free DNA 51
Apr 03, 2017: Digital Spatial Profiling Technology Enables Quantitative Protein Profiling in FFPE Tissue Providing Detailed Molecular Characterization of Immune Response to Tumors 52
Mar 29, 2017: NanoString Launches Multiple New Products at AACR 2017 to Advance Precision Oncology Research 54
Mar 27, 2017: NanoString Highlights a Record Number of nCounter-Based Research Abstracts in Precision Oncology and Predictive Biomarkers at the 2017 American Association of Cancer Research Annual Meeting 55
Mar 23, 2017: NanoString Launches New PlexSet Technology as an Alternative to qPCR for Multiplexed High-Throughput Gene Expression Studies 58
Feb 27, 2017: The Novartis Institutes for BioMedical Research and NanoString Technologies Demonstrate a Novel Approach for High-Plex 60
Feb 27, 2017: The Novartis Institutes for BioMedical Research and NanoString Technologies Demonstrates at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 61
Nov 30, 2016: NanoString Technologies Highlights Advances in Precision Oncology at the 58th Annual Meeting of the American Society of Hematology 62
Nov 18, 2016: NanoString Enhances Solid Tumor Profiling with 3D Biology Capabilities for Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue Samples 64
Nov 07, 2016: NanoString Launches Technology Access Program (TAP) for Transformative Platform for High-Plex Digital Spatial Profiling 65
Jun 02, 2016: NanoString Technologies Highlights Advances in Precision Oncology and Immunotherapy at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) 66
Apr 14, 2016: NanoString Technologies Unveils New nCounter Vantage Assays to Power Cancer Research With 3D Biology 69
02/09/2016: American Society of Clinical Oncology Clinical Practice Guideline Recommends Use of Prosigna (PAM50) for Guiding Treatment Decisions in Early Stage Breast Cancer Patients 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71
NanoString Technologies Inc, Medical Equipment, Key Facts, 2016 2
NanoString Technologies Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
NanoString Technologies Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
NanoString Technologies Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
NanoString Technologies Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
NanoString Technologies Inc, Deals By Market, 2011 to YTD 2017 9
NanoString Technologies Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
NanoString Technologies Raises US$0.2 Million In Venture Financing 12
NanoString Technologies Raises US$15 Million In Series E Financing 13
NanoString Technologies To Raise US$0.65 Million In Venture Financing 15
NanoString Technologies Secures US$20 Million In Series D Financing 16
NanoString Technologies Secures US$2.5 Million In Venture Financing 17
NanoString Technologies Enters into Distribution Agreement with SAM Laboratory 18
NanoString Technologies Enters into Agreement with NSABP Foundation 19
NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 20
NanoString Technologies Enters into Co-Development Agreement with HalioDx 21
NanoString Technologies Enters into Agreement with Cell Signaling Technology 22
Medivation and NanoString Technologies Enters into Partnership With Astellas Pharma 23
NanoString Enters into Research Agreement with CITN for Novel Cancer Immunotherapies 24
NanoString Enters into Co-Development Agreement with MD Anderson Cancer Center 25
NanoString Enters into Research Agreement with Brigham and Women’s Hospital 26
NanoString Enters into Co-Development Agreement with Celgene 27
NanoString Technologies Enters Into Option Agreement With Broad Institute To License Liver Cancer Gene Signature 28
NanoString Technologies Plans to Raise USD100 Million in Public Offering of Shares 29
NanoString Technologies Raises USD57.8 Million in Public Offering of Shares 30
NanoString to Raise USD40 Million in Public Offering of Shares 32
NanoString Technologies Completes Public Offering Of Shares For US$55 Million 33
NanoString Technologies Completes IPO Of Shares For US$54 Million 35
NanoString Technologies Inc, Key Competitors 37
NanoString Technologies Inc, Key Employees 38